Management of chronic hepatitis B virus infection: Current perspectives for the nurse practitioner

Journal of the American Academy of Nurse Practitioners

Volumn 18, Issue 5, 2006, Pages 203-215

  Perrillo, Robert ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Antiviral therapy; Chronic viral hepatitis; Hepatitis B; Screening

Indexed keywords

ADENINE; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE;

ACUTE DISEASE; ALGORITHM; DISEASE COURSE; DRUG COMBINATION; DRUG MONITORING; HEALTH; HEPATITIS B; HETEROZYGOTE; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER TUMOR; MASS SCREENING; NURSE ATTITUDE; NURSE PRACTITIONER; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; UNITED STATES; VACCINATION; VIROLOGY;

ACUTE DISEASE; ADENINE; ALGORITHMS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; DISEASE PROGRESSION; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; INFECTION CONTROL; INTERFERON-ALPHA; LIVER NEOPLASMS; MASS SCREENING; NURSE PRACTITIONERS; NURSE'S ROLE; PATIENT SELECTION; PRACTICE GUIDELINES; PRIMARY PREVENTION; UNITED STATES; VACCINATION; WORLD HEALTH;

EID: 33745504240     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2006.00124.x     Document Type: Article

References (58)

1. Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., et al 2003). Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125 (2 292 297.
2. Chan, CY., Lee, SD. Lo, KJ. (2004). Legend of hepatitis B vaccination: The Taiwan experience. Journal of Gastroenterology & Hepatology, 19 (2 121 126.
3. Chan, H. LY., Leung, N. WY., Hui, A. Y., Wong, V. W.-S., Liew, CT., Chim, A. ML., et al 2005). A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Annals of Internal Medicine, 142 (4 240 250.
4. Chang, T. T., Gish, R., de Man, R., Gadano, A., Sollano, J., Han, K. H., et al 2004). Entecavir is superior to lamivudine for the treatment of HBeAg+ chronic hepatitis B: Results of a phase III study ETV-022 in nucleoside-naïve patients [Abstract No. 70]. Hepatology, 40, 193A.
5. Chang, TT., Hadziyannis, S., Cianciara, J., Rizzeto, M., Schiff, E., Pastore, G., et al 2002). Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine [Abstract No. 550]. Hepatology, 36 (Suppl 300A.
6. Chen, CJ., Yang, HI. You, SL. (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma [Letter to the editor]. New England Journal of Medicine, 347, 1721 1722.
7. Chu, C. J., Hussain, M. Lok, A. S. F 2002). Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology, 36 (6 1408 1415.
8. Colonno, R., Rose, R. E., Levine, S. M., Pokornowski, K., Plym, M., Yu, C. F., et al 2005). Entecavir (ECV) resistance is not observed in nucleoside-naïve subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection [Abstract]. Journal of Hepatology, 42 (Suppl 173.
9. Cooksley, W. G 2004). Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Seminars in Liver Disease, 24 (Suppl. 1 45 53.
10. De Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., McIntyre, N., et al 2003). EASL international consensus conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (Long version). Journal of Hepatology, 39, S3 S25.
11. de Jongh, F. E., Janssen, H. L., de Man, R. A., Hop, W. C., Schalm, S. W., van Blankenstein, M 1992). Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology, 103 (5 1630 1635.
12. Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, HW. L., Goodman, Z., et al 1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine, 341, 1256 1263.
13. El-Serag, H. B. McGlynn, K. A 2004). Hepatitis B virus and hepatocellular carcinoma. Current Hepatitis Reports, 131, 132 137.
14. Hadziyannis, S., Tassopoulos, N., Chang, T. T., Heathcote, J., Kitis, G., Rizzetto, M., et al 2004). Three year study of adefovir dipivoxil demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) [Abstract No. 46]. Journal of Hepatology, 40 (Suppl 17.
15. Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, TT., Kitis, G., Rizzetto, M., et al 2005). Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New England Journal of Medicine, 352, 2673 2681.
16. Hou, J. Naoumov, N. V 2004). The emerging role of hepatitis B virus genotypes. Current Hepatitis Reports, 3, 145 151.
17. Janssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., et al 2005). Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet, 365 (9454 123 129.
18. Keeffe, E. B., Dieterich, D. T., Han, S. H., Jacobson, I. M., Martin, P., Schiff, E. R., et al 2004). A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clinical Gastroenterology and Hepatology, 2 (2 87 106.
19. Lai, CL., Leung, N. WY., Teo, EK., Tong, M., Wong, F., Hann, HW., et al 2003). Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B [Abstract No. 219]. Hepatology, 38 (Suppl 262A.
20. Lai, CL., Leung, N. W., Teo, EK., Tong, M., Wong, F., Hann, HW. Y., et al 2005). Phase IIb extended-treatment trial of telbivudine (LdT) vs lamivudine vs combination treatment in hepatitis B patients: Two-year results [Abstract]. Gastroenterology, 128, 320.
21. Lampertico, P., Del Ninno, E., Vigano, M., Romeo, R., Donato, M. F., Sablon, E., et al 2003). Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology, 37 (4 756 763.
22. Lau, G. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., et al 2005). Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New England Journal of Medicine, 352, 2682 2695.
23. Lewin, S. R., Ribeiro, R. M., Walters, T., Lau, G. K., Bowden, S., Locarnini, S., et al 2001). Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology, 34 (5 1012 1020.
24. Liaw, YF., Leung, N., Guan, R., Lau, G. K., Merican, I., McCaughan, G., et al 2005). Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver International, 25 (3 472 489.
25. Lok, A. S., Heathcote, E. J. Hoofnagle, J. H 2001). Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology, 120 (7 1828 1853.
26. Lok, A. S. F., Lai, CL., Leung, N., Yao, GB., Cui, ZY., Schiff, E. R., et al 2003). Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125 (6 1714 1722.
27. Lok, A. S. F. McMahon, B. J 2004). Practice guidelines committee, American association for the study of liver diseases (AASLD). Chronic hepatitis B: Update of recommendations. Hepatology, 39 (3 857 861.
28. Manensis, E. K. Hadziyannis, S. J 2001). Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 121 (1 101 109.
29. Marcellin, P., Chang, T., Lim, S., Sievert, W., Tong, M., Arterburn, S., et al 2005). Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients [Abstract]. Journal of Hepatology, 42 (Suppl 31.
30. Marcellin, P., Chang, TT., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., et al 2003). Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine, 348, 808 816.
31. Marcellin, P., Lau, G. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., et al 2004). Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine, 351, 1206 1217.
32. McQuillan, G. M., Kruszon-Moran, D., Kottiri, B. J., Curtin, L. R., Lucas, J. W. Kington, R. S 2004). Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: Data from NHANES III, 1988-1994. American Journal of Public Health, 94 (11 1952 1958.
33. MMWR in press). Hepatitis B virus infection: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part I: immunization of infants, children and adolescents. MMWR Morbidity and Mortality Weekly Report, 55 (6 158.
34. Nair, S. Perrillo, R. P 2001). Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology, 34 (5 1021 1026.
35. Niederau, C., Heintges, T., Niederau, M., Stremmel, W. Strohmeyer, G 1992). Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. European Journal of Medicine, 1 (7 396 402.
36. Perrillo, R. P 1993). Interferon in the management of chronic hepatitis B. Digestive Diseases and Sciences, 38 (4 577 593.
37. Perrillo, R. P 2005). Current treatment of chronic hepatitis B: Benefits and limitations. Seminars in Liver Disease, 25 (Suppl 20 28.
38. Perrillo, R., Hann, HW., Mutimer, D., Willems, B., Leung, N., Lee, W. M., et al 2004). Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology, 126 (1 81 90.
39. Perrillo, R. Nair, S 2003). Hepatitis B and D. In T. Boyer D. Zakim (Eds Hepatology. A Textbook of Liver Disease (4th ed. pp. 959 1016). Philadelphia : Saunders, Elsevier.
40. Perrillo, R. P., Lai, CL., Liaw, YF., Dienstag, J. L., Schiff, E. R., Schalm, S. W., et al 2002). Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology, 36 (1 186 194.
41. Perry, J. F., Poustchi, H., George, J., Farrell, G. C., McCaughan, G. W. Strasser, S. I 2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 5 (1 1 13.
42. Peters, M. G., Hann, H. W., Martin, P., Heathcote, E. J., Buggisch, P., Rubin, R., et al 2004). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 126 (1 91 100.
43. Piratvisuth, T., Luo, KX., Marcellin, P., Chang, Wy., Berg, T., et al 2005). Effect of ALT flares on efficacy and safety of PEGinterferon alfa-2a (40KD) (Pegasys®), PEGinterferon alfa-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB) [Abstract]. Journal of Hepatology, 42 (Suppl 189.
44. Piton, A., Poynard, T., Imbert-Bismut, F., Khalil, L., Delattre, J., Pelissier, F., et al., for the MULTIVIRC Group 1998). Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology, 27 (5 1213 1219.
45. Schiff, E. R., Lai, CL., Hadziyannis, S., Neuhaus, P., Terrault, N., Colombo, M., et al 2003). Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology, 38 (6 1419 1427.
46. Shouval, D., Lai, CL., Cheinquer, H., Lok, A., DeHertogh, D., Wilber, R., et al 2004). Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg- chronic hepatitis B: Results of phase III trial ETV-027 [Abstract LB. 07]. Hepatology, 40 (Suppl 728A.
47. Sung, J. J. Y., Lai, J. Y., Zeuzem, S., Chow, W. C., Heathcote, E., Perrillo, R., et al 2003). A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis [Abstract No. 69]. Journal of Hepatology, 38 (Suppl. 2 25.
48. Tenney, D. J., Langley, D. R., Oliver, A. J., Rose, R., Levine, S. M., Yu, C. F., et al 2004). Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase [Abstract No. 184]. Hepatology, 40 (Suppl 245A.
49. Thio, C. L 2003). Hepatitis B in the human immunodeficiency virus-infected patient: Epidemiology, natural history, and treatment. Seminars in Liver Disease, 23 (2 125 136.
50. van Bommel, F., Wunsche, T., Mauss, S., Reinke, P., Bergk, A., Schurmann, D., et al 2004). Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40 (6 1421 1425.
51. van Zonneveld, M., van Nunen, A. B., Niesters, H. G., de Man, R. A., Schalm, S. W. Janssen, H. L. A 2003). Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. Journal of Viral Hepatitis, 10 (4 294 297.
52. Weissberg, J. I., Andres, L. L., Smith, C. I., Weick, S., Nichols, J. E., Garcia, G., et al 1984). Survival in chronic hepatitis B. An analysis of 379 patients. Annals of Internal Medicine, 101 (5 613 616.
53. Westland, C., Delaney, W., IV., Yang, H., Chen, SS., Marcellin, P., Hadziyannis, S., et al 2003). Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology, 125 (1 107 116.
54. Wright, T. L 2004). Clinical trial results and treatment resistance with lamivudine in hepatitis B. Seminars in Liver Disease, 24 (Suppl. 1 31 36.
55. Xu, WM., Cui, YT., Wang, L., Yang, H., Liang, ZQ., Li, XM., et al 2004). Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B; a multicentre, randomized, double-blind, placebo-controlled study [Abstract No. 246]. Hepatology, 40 (Suppl 272A.
56. Yang, HI., Lu, SN., Liaw, YF., You, SL., Sun, CA., Wang, LY., et al 2002a). Hepatitis B e antigen and the risk of hepatocellular carcinoma. New England Journal of Medicine, 347, 168 174.
57. Yang, L. M., Xu, K. C., Zhao, Y. L., Wu, Z. R., Chen, T. F., Qin, Z. Y., et al 2002b). Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chinese Journal of Digestive Diseases, 3 (4 150 153.
58. Yao, J. D. C., Beld, M. G. H. M., Oon, L. L. E., Sherlock, C. H., Germer, J., Menting, S., et al 2004). Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 Assay. Journal of Clinical Microbiology, 42 (2 800 806.